Leerink Partners Maintains Their Hold Rating on Wave Life Sciences (WVE)

Leerink Partners analyst Mani Foroohar maintained a Hold rating on Wave Life Sciences (WVEResearch Report) on January 28 and set a price target of $7.00. The company’s shares closed last Monday at $2.45, close to its 52-week low of $2.03.

According to, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.9% and a 37.4% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Wave Life Sciences with a $10.00 average price target.

See the top stocks recommended by analysts >>

Based on Wave Life Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $36.42 million and GAAP net loss of $6.23 million. In comparison, last year the company earned revenue of $3.45 million and had a GAAP net loss of $33.1 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Read More on WVE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More